Literature DB >> 15317031

The reporting odds ratio and its advantages over the proportional reporting ratio.

Kenneth J Rothman1, Stephan Lanes, Susan T Sacks.   

Abstract

PURPOSE: The proportional reporting ratio (PRR) is the proportion of spontaneous reports for a given drug that are linked to a specific adverse outcome, divided by the corresponding proportion for all or several other drugs. The PRR is similar to the proportional mortality ratio (PMR), an old epidemiologic measure calculated from death registries and constructed in similar fashion to the PRR. The PMR has important deficiencies, however, which the PRR shares. Miettinen and Wang demonstrated that the PMR could be improved by reformulating it as an odds ratio and applying the principles of a case-control study to the measure. In this paper, we review the problem with the PRR and show how the corresponding odds ratio represents an improvement over the PRR.
METHODS: The method used is discussion and illustration by way of a hypothetical example.
RESULTS: The PRR does not estimate relative risk. If, however, a spontaneous report database is viewed as source data for a case-control study, the reporting odds ratio (ROR) can be used to estimate relative risk. Treating the data as source data for a case-control study allows for further reduction of bias by the judicious choice of controls.
CONCLUSIONS: Calculating the ROR in spontaneous report databases offers advantages over the PRR. It allows for estimation of the relative risk, and focuses attention on which people or reports should be included or excluded from the control series, permitting more deliberate elimination of biases. It also highlights the inherent weaknesses in spontaneous report data, which become more evident in light of the usual principles of control selection in case-control studies.

Entities:  

Mesh:

Year:  2004        PMID: 15317031     DOI: 10.1002/pds.1001

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  133 in total

1.  Identifying adverse events of vaccines using a Bayesian method of medically guided information sharing.

Authors:  Colin John Crooks; David Prieto-Merino; Stephen J W Evans
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  A novel method for signal detection of adverse drug reactions based on proportional reporting ratios.

Authors:  Jian-Xiang Wei; Ming Li; Yue-Hong Sun; Ye Lu; Hou-Ming Xu
Journal:  Pharm World Sci       Date:  2010-07-31

3.  An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies.

Authors:  Miguel-Angel Maciá-Martínez; Francisco J de Abajo; Gilly Roberts; Jim Slattery; Bharat Thakrar; Antoni F Z Wisniewski
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

4.  What Is the Plural of a 'Yellow' Anecdote?

Authors:  Stephen J W Evans
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

5.  Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase.

Authors:  Carmen Ferrajolo; Annalisa Capuano; Katia M C Verhamme; Martijn Schuemie; Francesco Rossi; Bruno H Stricker; Miriam C J M Sturkenboom
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

Review 6.  Perspectives on the use of data mining in pharmaco-vigilance.

Authors:  June Almenoff; Joseph M Tonning; A Lawrence Gould; Ana Szarfman; Manfred Hauben; Rita Ouellet-Hellstrom; Robert Ball; Ken Hornbuckle; Louisa Walsh; Chuen Yee; Susan T Sacks; Nancy Yuen; Vaishali Patadia; Michael Blum; Mike Johnston; Charles Gerrits; Harry Seifert; Karol Lacroix
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

7.  Gynaecomastia associated with proton pump inhibitors: a case series from the Spanish Pharmacovigilance System.

Authors:  Alfonso Carvajal; Diego Macias; Angélica Gutiérrez; Sara Ortega; María Sáinz; Luis H Martín Arias; Alfonso Velasco
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

8.  Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.

Authors:  Rohit P Ojha; Bradford E Jackson; Joseph E Tota; Tabatha N Offutt-Powell; Karan P Singh; Sejong Bae
Journal:  Hum Vaccin Immunother       Date:  2013-09-06       Impact factor: 3.452

9.  Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.

Authors:  Virginie Grouthier; Benedicte Lebrun-Vignes; Andrew M Glazer; Philippe Touraine; Christian Funck-Brentano; Antoine Pariente; Carine Courtillot; Anne Bachelot; Dan M Roden; Javid J Moslehi; Joe-Elie Salem
Journal:  Heart       Date:  2018-05-02       Impact factor: 5.994

10.  Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.

Authors:  Stephen W Reese; Eugene Cone; Maya Marchese; Brenda Garcia; Wesley Chou; Asha Ayub; Kerry Kilbridge; Gerald Weinhouse; Quoc-Dien Trinh
Journal:  Lung       Date:  2021-02-22       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.